InvestorsObserver
×
News Home

Should You Sell Agios Pharmaceuticals Inc (AGIO) in Biotechnology Industry?

Tuesday, June 22, 2021 02:51 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Sell Agios Pharmaceuticals Inc (AGIO) in Biotechnology Industry?

Agios Pharmaceuticals Inc (AGIO) is near the top in its industry group according to InvestorsObserver. AGIO gets an overall rating of 50. That means it scores higher than 50 percent of stocks. Agios Pharmaceuticals Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 110 out of 148 industries.

Overall Score - 50
AGIO has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on AGIO!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 50 means the stock is more attractive than 50 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Agios Pharmaceuticals Inc Stock Today?

Agios Pharmaceuticals Inc (AGIO) stock has fallen -7.13% while the S&P 500 is higher by 0.42% as of 2:48 PM on Tuesday, Jun 22. AGIO is lower by -$4.37 from the previous closing price of $61.27 on volume of 371,330 shares. Over the past year the S&P 500 has risen 36.07% while AGIO is higher by 18.00%. AGIO earned $22.80 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 2.5.

Click Here to get the full Stock Score Report on Agios Pharmaceuticals Inc (AGIO) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App